• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Pharmacy Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 9 (2025)
Volume Volume 8 (2024)
Volume Volume 7 (2023)
Volume Volume 6 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2021)
Volume Volume 4 (2020)
Volume Volume 3 (2019)
Volume Volume 2 (2018)
Volume Volume 1 (2017)
Hassan, A., Sarg, M., Bayoumi, A., Abdul Rahman, F. (2022). Phenylimidazoles Scaffolds as Potent Anticancer Agents (Part I). Journal of Advanced Pharmacy Research, 6(4), 192-206. doi: 10.21608/aprh.2022.145308.1183
Aisha Hassan; Marwa Sarg; Ashraf Bayoumi; Fatma Abdul Rahman. "Phenylimidazoles Scaffolds as Potent Anticancer Agents (Part I)". Journal of Advanced Pharmacy Research, 6, 4, 2022, 192-206. doi: 10.21608/aprh.2022.145308.1183
Hassan, A., Sarg, M., Bayoumi, A., Abdul Rahman, F. (2022). 'Phenylimidazoles Scaffolds as Potent Anticancer Agents (Part I)', Journal of Advanced Pharmacy Research, 6(4), pp. 192-206. doi: 10.21608/aprh.2022.145308.1183
Hassan, A., Sarg, M., Bayoumi, A., Abdul Rahman, F. Phenylimidazoles Scaffolds as Potent Anticancer Agents (Part I). Journal of Advanced Pharmacy Research, 2022; 6(4): 192-206. doi: 10.21608/aprh.2022.145308.1183

Phenylimidazoles Scaffolds as Potent Anticancer Agents (Part I)

Article 3, Volume 6, Issue 4, October 2022, Page 192-206  XML PDF (464.86 K)
Document Type: Research Article
DOI: 10.21608/aprh.2022.145308.1183
View on SCiNiTO View on SCiNiTO
Authors
Aisha Hassan1; Marwa Sarg2; Ashraf Bayoumi2; Fatma Abdul Rahman email 3
1Department of Organic Chemistry, Faculty of Science (Girls), Al-Azhar University, Cairo, Egypt.
2Department of Organic Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
3Department of Organic Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Abstract
Objective: Novel anticancer agents were designed to be synthesized comprising the essential features for anticancer activity considering Leucettamine B as a lead compound. Method: 3-Phenyl-2-thioxoimidazolidin-4-one 1 has been utilized for synthesis of various fused pyrrolo[1,2-e]imidazole 4, 8a,b, 11, 14, 16, 18, 20, 21, 23, 25 analogues through different chemical reactions. Results: Structures of these compounds were confirmed by spectral and elemental analyses Thirteen of the newly synthesized compounds were selected by the NCI – Maryland-U.S.A. and were tested for their anticancer activity in an initial single high dose in the full NCI 60 cell line panel. Conclusion: 5-amino-2,3,7,7a-tetrahydro-7-(4-methoxyphenyl)-1-oxo-2-phenyl-3-thioxo-1H-pyrrolo[1,2-e]imidazole-6-carbonitrile; 4, 1-(7-(4-chlorophenyl)-3,7-dihydro-1,5-dihydroxy-2-phenyl-3-thioxo-2H-pyrrolo[1,2-e]imidazol-6yl) ethenone; 21, were found to possess very selective potent anticancer activity against certain cancer cell lines.
Keywords
Anticancer; Pyrrolo[1; 2-e]imidazole; Leucettamine
Main Subjects
Section B: Pharmaceutical Analytical & Organic Chemistry, Medicinal & Biochemistry
Statistics
Article View: 281
PDF Download: 425
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.